# A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

> **NCT01777243** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** GSK2398852
- **DRUG:** GSK2315698

## Key facts

- **NCT ID:** NCT01777243
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-13
- **Primary completion:** 2015-12-22
- **Final completion:** 2015-12-22
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-07-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777243, "A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01777243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*